The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
110467745 11046774 5 F 2007 20160914 20150420 20160924 EXP CA-AMGEN-CANSP2015036531 AMGEN 16.00 YR T F Y 0.00000 20160924 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
110467745 11046774 1 PS ENBREL ETANERCEPT 1 Subcutaneous 50 MG, 1 EVERY 1 WEEK D 103795 50 MG UNKNOWN FORMULATION /wk
110467745 11046774 2 SS METHOTREXATE. METHOTREXATE 1 Unknown 25 MG, QWK 0 25 MG /wk
110467745 11046774 3 SS SULFASALAZINE. SULFASALAZINE 1 Oral 2 G, BID 0 2 G BID
110467745 11046774 4 SS CIMZIA CERTOLIZUMAB PEGOL 1 Unknown 200 MG, Q2MO 0 200 MG
110467745 11046774 5 SS ACTEMRA TOCILIZUMAB 1 Intravenous (not otherwise specified) 8 MG/KG, Q4WK 0 8 MG/KG
110467745 11046774 6 SS ACTEMRA TOCILIZUMAB 1 Subcutaneous UNK 0
110467745 11046774 7 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) 5 MG/KG, EVERY 8 WEEKS 0 5 MG/KG
110467745 11046774 8 SS HUMIRA ADALIMUMAB 1 Subcutaneous 40 MG, Q2WK 0 40 MG QOW
110467745 11046774 9 SS ORENCIA ABATACEPT 1 Intravenous (not otherwise specified) 750 MG, EVERY 4 WEEKS 0 750 MG
110467745 11046774 10 SS LEFLUNOMIDE. LEFLUNOMIDE 1 Unknown 20 MG, 1 EVERY 1 DAY 0 20 MG TABLET
110467745 11046774 11 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Unknown 20 MG, 1 EVERY 1 WEEK 0 20 MG /wk
110467745 11046774 12 C XELJANZ TOFACITINIB CITRATE 1 Oral 5 MG, BID 0 5 MG BID
110467745 11046774 13 C PLAQUENIL HYDROXYCHLOROQUINE SULFATE 1 Oral 200 MG, BID 0 200 MG BID

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
110467745 11046774 1 Rheumatoid arthritis
110467745 11046774 2 Rheumatoid arthritis
110467745 11046774 3 Rheumatoid arthritis
110467745 11046774 4 Product used for unknown indication
110467745 11046774 5 Product used for unknown indication
110467745 11046774 7 Product used for unknown indication
110467745 11046774 8 Product used for unknown indication
110467745 11046774 9 Product used for unknown indication
110467745 11046774 10 Product used for unknown indication
110467745 11046774 11 Product used for unknown indication
110467745 11046774 12 Rheumatoid arthritis

Outcome of event

Event ID CASEID OUTC COD
110467745 11046774 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
110467745 11046774 Abdominal discomfort
110467745 11046774 Arthropathy
110467745 11046774 Crohn's disease
110467745 11046774 Drug hypersensitivity
110467745 11046774 Drug ineffective
110467745 11046774 Gait disturbance
110467745 11046774 Joint swelling

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
110467745 11046774 2 201005 0
110467745 11046774 3 201203 201207 0
110467745 11046774 4 201207 201404 0
110467745 11046774 5 201406 201410 0
110467745 11046774 12 20141030 0
110467745 11046774 13 201203 0